Roche Holding

RHHBY-OTC

OTCMKTS:RHHBY

42.42
0.67 (1.60%)
F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
More at Wikipedia

Analysis and Opinions about RHHBY-OTC

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
October 3, 2018

(A Top Pick October 31/17 Up 10%) A steady business that pays a good dividend. You should make 10% a year return. There is a good pipeline of drug projects yet to come. Yield 3.5%

Show full opinionHide full opinion

(A Top Pick October 31/17 Up 10%) A steady business that pays a good dividend. You should make 10% a year return. There is a good pipeline of drug projects yet to come. Yield 3.5%

DON'T BUY
DON'T BUY
November 1, 2017

Made an acquisition quite a while ago of a biotech firm that comes up with all the future products. However, they are starting with some of the research that are in stage I and stage II. Sales were up 5% in the last quarter, but have seen a decline of 1% overall. The stock hasn't done a lot this year. Until this actually comes up with something that is going to be a gang buster, he would stay away.

Show full opinionHide full opinion
Roche Holding (RHHBY-OTC)
November 1, 2017

Made an acquisition quite a while ago of a biotech firm that comes up with all the future products. However, they are starting with some of the research that are in stage I and stage II. Sales were up 5% in the last quarter, but have seen a decline of 1% overall. The stock hasn't done a lot this year. Until this actually comes up with something that is going to be a gang buster, he would stay away.

TOP PICK
TOP PICK
October 31, 2017

A Swiss company. Has been a laggard this year, and pulled back recently. Have some interesting drugs for multiple sclerosis, immunology on cancer. Trades 15%-20% cheaper than the rest of the pharmas. Dividend yield of 3.6%. (Analysts' price target is CHF 261.00)

Show full opinionHide full opinion
Roche Holding (RHHBY-OTC)
October 31, 2017

A Swiss company. Has been a laggard this year, and pulled back recently. Have some interesting drugs for multiple sclerosis, immunology on cancer. Trades 15%-20% cheaper than the rest of the pharmas. Dividend yield of 3.6%. (Analysts' price target is CHF 261.00)

PAST TOP PICK
PAST TOP PICK
January 25, 2017

(A Top Pick Oct 11/16. Down 2.05%.) A very deep pipeline of drugs and hidden value. It gives you a 3%+ yield. Great company.

Show full opinionHide full opinion
Roche Holding (RHHBY-OTC)
January 25, 2017

(A Top Pick Oct 11/16. Down 2.05%.) A very deep pipeline of drugs and hidden value. It gives you a 3%+ yield. Great company.

TOP PICK
TOP PICK
January 25, 2017

Deep pipeline. Attractively valued. It has a couple of drugs that are nearing approval in the 1st half of this year. One is in the breast cancer area and one in the bio similar area. Dividend yield of 3.46%. (Analysts’ price target is CHF 278.65.)

Show full opinionHide full opinion
Roche Holding (RHHBY-OTC)
January 25, 2017

Deep pipeline. Attractively valued. It has a couple of drugs that are nearing approval in the 1st half of this year. One is in the breast cancer area and one in the bio similar area. Dividend yield of 3.46%. (Analysts’ price target is CHF 278.65.)

BUY
BUY
October 27, 2016

or RHHBY-5. You can buy the ADR. They have a strong pipeline and can grow it. He thinks they will continue to do well. When do you buy them considering the US election? Pharma do not do well before a US election. You buy these things going into the election and you get a bounce out of them.

Show full opinionHide full opinion
Roche Holding (RHHBY-OTC)
October 27, 2016

or RHHBY-5. You can buy the ADR. They have a strong pipeline and can grow it. He thinks they will continue to do well. When do you buy them considering the US election? Pharma do not do well before a US election. You buy these things going into the election and you get a bounce out of them.

TOP PICK
TOP PICK
October 11, 2016

Attractively valued at about 15X 2017 earnings. This has had 30 years of dividend growth. In addition to valuation, this has a very attractive pipeline with a hidden value of new products coming up. They also have a drug for multiple sclerosis that is due for regulatory action on December 28. Dividend yield of 3.39%.

Show full opinionHide full opinion
Roche Holding (RHHBY-OTC)
October 11, 2016

Attractively valued at about 15X 2017 earnings. This has had 30 years of dividend growth. In addition to valuation, this has a very attractive pipeline with a hidden value of new products coming up. They also have a drug for multiple sclerosis that is due for regulatory action on December 28. Dividend yield of 3.39%.

DON'T BUY
DON'T BUY
April 4, 2016

They don’t have enough products in the pipeline. Many pharmas are struggling right now.

Show full opinionHide full opinion

They don’t have enough products in the pipeline. Many pharmas are struggling right now.

COMMENT
COMMENT
February 24, 2015

This is interesting right now based on the value proposition that is going into the pharma space. They have a lot of M&A activity there. This has some growth potential because of breast cancer. Fundamentally the company looks solid and the dividend looks good.

Show full opinionHide full opinion
Roche Holding (RHHBY-OTC)
February 24, 2015

This is interesting right now based on the value proposition that is going into the pharma space. They have a lot of M&A activity there. This has some growth potential because of breast cancer. Fundamentally the company looks solid and the dividend looks good.

Showing 1 to 9 of 9 entries
  • «
  • 1
  • »